Daniel Tillett Buys 22,000 Shares of Race Oncology (ASX:RAC) Stock

Race Oncology Limited (ASX:RAC) insider Daniel Tillett bought 22,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 26th. The shares were bought at an average price of A$2.67 per share, with a total value of A$58,740.00.

Race Oncology Stock Performance

The company has a market cap of $211.94 million, a PE ratio of -14.60 and a beta of 1.74.

Race Oncology Company Profile

Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection.